Tumor vasculature: The Achilles' heel of cancer?

International Journal of Cancer Research

Volumn 2, Issue 2, 2006, Pages 176-187

  Mocellin, Simone ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Angiogenesis; Cancer; Clinical trials; Drugs; Therapy; Tumor vasculature

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANTIHYPERTENSIVE AGENT; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CELECOXIB; COMBRETASTATIN A4 PHOSPHATE; CYCLOOXYGENASE 2 INHIBITOR; DEHYDRODIDEMNIN B; FLUOROURACIL; FOLINIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; IMATINIB; IMC 1C11; IRINOTECAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; OXALIPLATIN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB;

ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERTENSION; KIDNEY CANCER; NAUSEA; NONHUMAN; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; TUMOR VASCULARIZATION;

EID: 33646413139     PISSN: 18119727     EISSN: 18119735     Source Type: Journal    
DOI: 10.3923/ijcr.2006.176.187     Document Type: Article

References (33)

1. Altorki, N.K., R.S. Keresztes, J.L. Port, D.M. Libby and R.J. Korst et al., 2003. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J. Clin. Oncol., 21: 2645-2650.
2. Arora, A. and E.M. Scholar, 2005. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther., 315: 971-979.
3. Bergsland, E.K, 2004. Update on clinical trials targeting vascular endothelial growth factor in cancer. Am. J. Health Syst. Pharm., 61: S12-20.
4. Bilenker, J.H., K.T. Flaherty, M. Rosen, L. Davis and M. Gallagher et al., 2005. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin. Cancer Res., 11: 1527-1533.
5. Carmeliet, P., 2003. Angiogenesis in health and disease. Natl. Med., 9: 653-660.
6. Clark, J.W., J.P. Eder, D. Ryan, C. Lathia and H.J. Lenz, 2005. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res., 11: 5472-5480.
7. Eder, Jr. J.P., J.G. Supko, J.W. Clark, T.A. Puchalski and R. Garcia-Carbonero et al., 2002. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J. Clin. Oncol., 20: 3772-84.
8. Eskens, F.A., H. Dumez, R. Hoekstra, A. Perschl and C. Brindley et al., 2003. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur. J. Cancer, 39: 917-926.
9. Fayette, J., J.C. Soria and J.P. Armand, 2005. Use of angiogenesis inhibitors in tumour treatment. Eur. J. Cancer, 41: 1109-1116.
10. Ferrara, N., H.P. Gerber and J. LeCouter, 2003. The biology of VEGF and its receptors. Natl. Med., 9: 669-676.
11. Folberg, R., M.J. Hendrix and A.J. Maniotis, 2000. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol., 156: 361-381.
12. Hoekstra, R., F.Y. de Vos, F.A. Eskens, J.A. Gietema and A. Van der Gaast et al., 2005. Phase I safety, pharmacokinetic and pharmacodynamic study of the thrombospondin-I-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J. Clin. Oncol., 23: 5188-5197.
13. Hurwitz, H., L. Fehrenbacher, W. Novotny, T. Cartwright and J. Hainsworth et al., 2004. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 350: 2335-2342.
14. Jimeno, J, J.A. Lopez-Martin, A. Ruiz-Casado, M.A. Izquierdo, P.J. Scheuer and K. Rinehart, 2004. Progress in the clinical development of new marine-derived anticancer compounds. Anticancer Drugs, 15: 321-329.
15. Kamiyama, M., Y. Ichikawa, T. Ishikawa, T. Chishima and S. Hasegawa et al., 2002. VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice. Cancer Gene. Ther., 9: 197-201.
16. Kim, K.J., B. Li, J. Winer, M. Armanini and N. Gillett et al., 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 362: 841-844.
17. Kindler, H.L., G. Friberg, D.A. Singh, G. Locker and S. Nattam et al., 2005. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol., 23: 8033-8040.
18. Klagsbrun, M. and A. Eichmann, 2005. A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis. Cytokine Growth Factor Rev., 16: 535-48.
19. Kuenen, B.C., G. Giaccone, R. Ruijter, A. Kok and C. Schalkwijk et al., 2005. Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clin. Cancer Res., 11: 6240-6246.
20. Lyden, D., K. Hattori, S. Dias, C. Costa and P. Blaikie et al., 2001. Impaired recruitment of bonemarrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Natl. Med., 7: 1194-1201.
21. Mancuso, A. and C.N. Sternberg, 2005. New treatments for metastatic kidney cancer. Can. J. Urol., 12 Suppl 1:66-70; discussion 105.
22. McNeel, D.G., J. Eickhoff, F.T. Lee, D.M. King and D. Alberti et al., 2005. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin. Cancer Res., 11: 7851-7860.
23. Niederman, T.M., Z. Ghogawala, B.S. Carter, H.S. Tompkins, M.M. Russell and R.C. Mulligan, 2002. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc. Natl. Acad. Sci. USA., 99: 7009-7014.
24. Peters, B.A., L.A. Diaz, K. Polyak, L. Meszler and K. Romans et al., 2005. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Natl. Med., 11: 261-262.
25. Posey, J.A., T.C. Ng, B. Yang, M.B. Khazaeli and M.D. Carpenter et al., 2003. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin. Cancer Res., 9: 1323-1332.
26. Pruthi, R.S., J.E. Derksen and D. Moore, 2004. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Intl., 93: 275-278.
27. Stevenson, J.P., M. Rosen, W. Sun, M. Gallagher and D.G. Haller et al., 2003. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol., 21: 4428-4438.
28. Sund, M., Y. Hamano, H. Sugimoto, A. Sudhakar and M. Soubasakos et al., 2005. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc. Natl. Acad. Sci. USA., 102: 2934-2939.
29. Tortora, G., D. Melisi and F. Ciardiello, 2004. Angiogenesis: A target for cancer therapy. Curr. Pharm. Des., 10: 11-26.
30. Weng, D.E., P.A. Masci, S.F. Radka, T.E. Jackson and P.A. Weiss et al., 2005. A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Mol. Cancer Ther., 4: 948-955.
31. Yancopoulos, G.D., S. Davis, N.W. Gale, J.S. Rudge, S.J. Wiegand and J. Holash, 2000. Vascular-specific growth factors and blood vessel formation. Nature, 407: 242-248.
32. Yang, J.C., L. Haworth, R.M. Sherry, P. Hwu and D.J. Schwartzentruber et al., 2003. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med., 349: 427-434.
33. Zakarija, A. and G. Soff, 2005. Update on angiogenesis inhibitors. Curr. Opin. Oncol., 17: 578-583.